MAXHEALTH - Max Healthcare
📢 Recent Corporate Announcements
Max Healthcare Institute Limited has received a favorable Rectification Order from the GST Department in New Delhi. The authority has withdrawn a previously raised tax demand of ₹55.20 crore related to alleged excess Input Tax Credit. This follows a rectification application filed by the company against an order dated December 30, 2025. The total withdrawal of the demand removes a potential financial liability for the company.
- GST authority has withdrawn the entire demand of ₹55,20,45,266 raised against the company.
- The dispute originated from an order dated December 30, 2025, regarding excess Input Tax Credit.
- The Rectification Order was received from the Office of the GST Officer, Ward 96, New Delhi.
- The authority accepted the company's submissions, resulting in zero penalty or compensation.
Max Healthcare is expanding its footprint into Eastern India by acquiring a 58.39% stake in the 250-bed Kalinga Hospital in Bhubaneswar for ₹300 crore. The acquisition includes a prime 10-acre land parcel with significant brownfield potential to expand capacity to over 1,000 beds. To finance this, the board has approved a ₹300 crore External Commercial Borrowing (ECB) and an additional ₹100 crore loan for hospital infrastructure upgrades. Kalinga Hospital showed strong growth with FY25 revenues reaching ₹135.63 crore compared to ₹105.65 crore in FY24.
- Acquisition of 58.39% stake in Kalinga Hospital Ltd for an equity value of ₹300 Crore.
- Target facility is a 250-bed NABH accredited hospital with potential to scale to 1,000+ beds on a 10-acre campus.
- KHL revenue grew 28% year-on-year to ₹135.63 Crore in FY25.
- Approved ₹300 Crore Senior Secured Term Loan (ECB) from Standard Chartered Bank to fund the deal.
- Additional ₹100 Crore loan approved for KHL's renovation, upgradation, and equipment costs.
Max Healthcare Institute Limited (MHIL) has entered into a share purchase agreement to acquire a 58.4% controlling stake in Kalinga Hospital Limited (KHL) for an equity value of ₹300 Crore. KHL operates a 250-bed multi-specialty hospital in Bhubaneswar, Odisha, and reported a revenue of ₹135.63 Crore in FY 2024-25. The acquisition includes a 10-acre land parcel, offering significant brownfield potential to expand the facility to over 1,000 beds. To support this, MHIL has approved ₹300 Crore in External Commercial Borrowings and will provide a ₹100 Crore loan for hospital renovation and upgradation.
- Acquisition of 58.4% stake in Kalinga Hospital Ltd for ₹300 Crore equity value.
- Target hospital has 250 beds with potential to expand to 1,000+ beds on a 10-acre campus.
- KHL's revenue grew significantly from ₹90.39 Crore in FY23 to ₹135.63 Crore in FY25.
- Approved ₹300 Crore in External Commercial Borrowings (ECB) to finance the acquisition.
- Additional ₹100 Crore loan approved for KHL's renovation and equipment upgradation.
Max Healthcare is expanding its footprint into Eastern India by acquiring a 58.39% controlling stake in the 250-bed Kalinga Hospital in Bhubaneswar for an equity value of ₹300 Crore. The acquisition includes a prime 10-acre land parcel, offering significant brownfield potential to expand the facility to over 1,000 beds. To support the acquisition and subsequent upgrades, the board has approved ₹300 Crore in External Commercial Borrowings and an additional ₹100 Crore loan for hospital renovation. Kalinga Hospital demonstrated strong growth with FY25 revenue reaching ₹135.63 Crore, up from ₹90.39 Crore in FY23.
- Acquisition of 58.39% stake in Kalinga Hospital Ltd for ₹300 Crore equity value.
- Immediate addition of 250 beds with long-term potential to scale to 1,000+ beds on a 10-acre campus.
- Target company revenue grew from ₹90.39 Crore in FY23 to ₹135.63 Crore in FY25.
- Board approved ₹300 Crore ECB for financing and up to ₹100 Crore loan for facility upgradation.
- Strategic entry into the Bhubaneswar market, serving Odisha, West Bengal, Jharkhand, and Chhattisgarh.
Max Healthcare has entered into a share purchase agreement to acquire a 58.39% controlling stake in Kalinga Hospital Limited (KHL) in Bhubaneswar for ₹300 Crore. This acquisition marks the company's entry into the Odisha market, utilizing a 250-bed facility with significant brownfield potential to expand to over 1,000 beds on its 10-acre campus. The transaction will be funded through a ₹300 Crore External Commercial Borrowing (ECB) from Standard Chartered Bank. Additionally, the board approved a ₹100 Crore loan for KHL's infrastructure upgrades and re-appointed Narayan K. Seshadri as a director for three years.
- Acquisition of 58.39% stake in Kalinga Hospital Ltd for an equity value of ₹300 Crore.
- Target hospital is a 250-bed NABH accredited facility in Bhubaneswar with FY25 revenue of ₹135.63 Crore.
- Strategic 10-acre land parcel allows for long-term expansion potential to over 1,000 beds.
- Financing secured via a ₹300 Crore Senior Secured Term Loan (ECB) from Standard Chartered Bank.
- Board approved an additional ₹100 Crore loan to KHL for renovation and infrastructure upgrades.
Max Healthcare Institute Limited has approved the allotment of 57,461 equity shares to employees following the exercise of vested stock options under the ESOP Scheme 2022. The shares were issued at an exercise price of ₹350 per share, which includes a premium of ₹340. This allotment increases the total paid-up equity share capital of the company to 97,31,92,502 shares. The dilution resulting from this issuance is negligible, representing less than 0.01% of the total equity base.
- Allotment of 57,461 equity shares of face value ₹10 each to eligible employees.
- Exercise price fixed at ₹350 per share, including a premium of ₹340.
- Total paid-up equity capital increased from ₹973.13 crore to ₹973.19 crore.
- Post-allotment, the total number of equity shares stands at 97,31,92,502.
- The company stated the allotment is not material under SEBI Regulation 30.
Max Healthcare Institute Limited has announced the closure of its trading window for all designated persons and their immediate relatives starting April 1, 2026. This is a standard regulatory procedure ahead of the announcement of financial results for the fourth quarter and the full financial year ending March 31, 2026. The trading window will remain closed until 48 hours after the board approves and declares the financial results. The specific date for the board meeting to discuss these results will be communicated at a later date.
- Trading window closure starts from Wednesday, April 1, 2026.
- Closure pertains to the financial results for Q4 and the full year ending March 31, 2026.
- Restriction applies to all designated persons and their immediate relatives under SEBI regulations.
- Window will reopen 48 hours after the official declaration of the financial results.
Max Healthcare Institute Limited has announced the formal dissolution of its step-down wholly-owned subsidiary, ET Planners Private Limited, following an order from the NCLT New Delhi Bench. The voluntary liquidation process involved transferring the subsidiary's entire business undertaking, including assets and liabilities, to its parent entity, Alps Hospital Limited, on a going concern basis. Creditors representing claims of ₹41.72 crore provided their consent for this transfer. The company has officially stated that this restructuring will have no material impact on its consolidated financials or accounting policies.
- NCLT New Delhi Bench passed the final dissolution order for ET Planners Private Limited on March 25, 2026.
- The entire business undertaking was transferred to Alps Hospital Limited (a 100% subsidiary of Max Healthcare) on a going concern basis.
- Creditors amounting to ₹41.72 crore gave No Objection Certificates (NOCs) for the transfer of their claims.
- The liquidated entity had a nominal paid-up share capital of ₹1,16,620 at the time of initiation.
- Management confirmed the liquidation will not affect business operations or result in any material financial impact.
Max Healthcare Institute Limited has approved the grant of 50,000 stock options to an eligible employee under its Employee Stock Option Scheme 2022. Each option is convertible into one equity share of ₹10 face value at an exercise price of ₹900. The vesting period for these options ranges from one to five years, with an exercise window of three years post-vesting. This is a routine administrative action aimed at employee retention and incentive alignment.
- Grant of 50,000 stock options under the MHIL ESOP - 2022 scheme
- Exercise price fixed at ₹900 per stock option
- Vesting schedule ranges between 1 and 5 years from the grant date
- Options must be exercised within 3 years from the respective vesting dates
- Each option is convertible into one fully paid-up equity share of ₹10 face value
Max Healthcare Institute Limited has approved the grant of 50,000 stock options to an eligible employee under its Employee Stock Option Scheme 2022. The exercise price for these options is set at ₹900 per share, which will be convertible into an equal number of equity shares of face value ₹10 each. The vesting period for these options ranges from one to five years, subject to specific pre-vesting conditions. This grant is a routine corporate action aimed at talent retention and aligning employee performance with shareholder interests.
- Grant of 50,000 stock options convertible into 50,000 fully paid-up equity shares
- Exercise price fixed at ₹900 per stock option
- Vesting schedule ranges from a minimum of 1 year to a maximum of 5 years from the grant date
- Options must be exercised within 3 years from the respective vesting dates
- The grant is compliant with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021
Max Healthcare Institute Limited has announced its participation in the J.P. Morgan India Forum 2026. The event is scheduled for March 9 and 10, 2026, and will be held physically at the Fullerton Hotel in Singapore. The company's Chairman and Managing Director will lead the engagement, conducting both one-on-one and group meetings with institutional investors. The company has clarified that no unpublished price sensitive information will be shared during these interactions.
- Investor conference scheduled for March 9 and 10, 2026, in Singapore.
- Chairman and Managing Director to represent the company in one-on-one and group meetings.
- Participation in the J.P. Morgan India Forum 2026 to engage with global institutional investors.
- Company confirms no unpublished price sensitive information (UPSI) will be disclosed.
Max Healthcare Institute Limited has received a partially favorable appeal order from the Commissioner of Central Tax Appeal-II, Delhi. The original GST demand for the period FY 2017-18 to FY 2020-21, which totaled approximately ₹5.13 crore including penalties, has been significantly reduced. The revised demand now stands at approximately ₹1.77 crore, including GST, interest, and penalties. The company intends to file a further appeal to contest the remaining balance of the demand.
- Appeal order deleted tax demand of ₹1.67 crore and penalty of ₹1.68 crore from the original assessment.
- Total revised demand stands at ₹1.77 crore, down from the previous demand of over ₹5.13 crore.
- The dispute relates to alleged discrepancies in Input Tax Credit (ITC) and tax recovery for FY 2017-18 to FY 2020-21.
- Management confirms no other material impact on financial or operational activities and will pursue further appeals.
Max Healthcare showcased its position as India's largest hospital chain by market cap (₹1.02 lakh crore) with a strong 4-year EBITDA CAGR of 38% and Revenue CAGR of 24%. The company currently operates over 5,200 beds across 20 facilities, maintaining a high occupancy rate of 76% and a robust ROCE of 26% for 9M FY26. Growth is being driven by aggressive inorganic expansion, including recent acquisitions in Lucknow, Nagpur, and Noida, alongside significant brownfield expansions in Mumbai and Mohali.
- Achieved a 38% EBITDA CAGR and 24% Revenue CAGR over the last 4 years (FY21-FY25)
- Current capacity exceeds 5,200 beds with 73% located in high-demand metro areas
- Maintained a strong Return on Capital Employed (ROCE) of approximately 26% for 9M FY26
- Institutional investors (FIIs and DIIs) hold a combined stake of over 71% as of December 2025
- Ongoing expansion includes a 160-bed tower in Mohali and a 268-bed tower at Nanavati-Max
Max Healthcare reported a 10% YoY revenue growth to INR 2,608 crore for Q3 FY26, although operating EBITDA margins contracted to 26.1% from 27.3% YoY. Performance was impacted by transitory factors including a temporary disruption in cashless services with insurers and revised CGHS pricing for chemotherapy drugs. Despite these headwinds, occupancy remained healthy at 74% on an expanded bed base, and ARPOB grew 3% YoY to INR 77,900. The company continues its aggressive expansion with new beds commissioned in Mumbai and Mohali, and a board-approved 260-bed addition at Max Dwarka.
- Gross revenue increased 10% YoY to INR 2,608 crore, while operating EBITDA grew 4% to INR 648 crore.
- Average Revenue Per Occupied Bed (ARPOB) reached INR 77,900, reflecting a 3% YoY growth.
- International patient revenue grew 14% YoY, now accounting for 9% of total hospital revenue.
- Brownfield expansion is on track with 116 beds commissioned across Nanavati and Mohali units in Q3.
- Net debt-to-EBITDA remains conservative at less than 1x, with INR 281 crore free cash flow generated during the quarter.
Max Healthcare Institute Limited (MAXHEALTH) released its latest investor presentation, highlighting its position as India's largest hospital chain by market capitalization at ₹1.02 lakh crore. The company demonstrated robust financial performance with a 4-year EBITDA CAGR of 38% and a revenue CAGR of 24%. Operational efficiency remains high with a 9M FY26 occupancy rate of approximately 76% and a Return on Capital Employed (ROCE) of 26%. The presentation outlines a massive expansion pipeline across Delhi NCR, Mumbai, Lucknow, and Pune to further scale its 5,200+ bed capacity.
- Market capitalization stands at ₹1.02 lakh crore ($11.3 billion) as of December 31, 2025.
- Achieved a 38% EBITDA CAGR and 24% Revenue CAGR over the last 4 years.
- Current capacity exceeds 5,200 beds across 20 facilities with 73% of beds located in metro cities.
- Maintained strong operational metrics with ~76% occupancy and ~26% ROCE for 9M FY26.
- Significant expansion pipeline includes a ~1,000-bed project in Gurugram and a ~450-bed hospital development in Pune.
Financial Performance
Revenue Growth by Segment
Standalone revenue from operations grew 13.8% to INR 2,663.60 Cr in FY25. Healthcare services contributed INR 2,411.33 Cr (90.5% of standalone revenue), Operation and Management (O&M) fees contributed INR 86.86 Cr (3.3%), and pharmaceutical supply sales contributed INR 108.63 Cr (4.1%). Consolidated network revenue grew 16% in FY24 and 21% YoY in Q2 FY26.
Geographic Revenue Split
The company has a high geographic concentration with approximately 75% to 78% of its bed capacity located in metro cities, specifically the Delhi-NCR region. The remaining capacity is distributed across Mumbai, Mohali, Lucknow, and Nagpur.
Profitability Margins
Consolidated operating margins stood at 28.23% in FY24, an improvement from 27.19% in FY23. Standalone other income increased to INR 366.54 Cr in FY25, supporting net profitability. Max Lab (diagnostics) reports an EBITDA margin of 16%, while Max@Home reports approximately 20%.
EBITDA Margin
Consolidated operating EBITDA increased by 23% YoY in Q2 FY26. The MHC network operating margin was 26.87% in FY24. Profitability is driven by a 12.5% increase in Average Revenue Per Occupied Bed (ARPOB), which rose from INR 67,400 in FY23 to INR 75,800 in FY24.
Capital Expenditure
The company plans to double its capacity over the next five years through organic and inorganic routes. A significant recent investment includes the acquisition of the remaining 36.35% stake in JHL for INR 624.70 Cr in November 2024. Expansion is largely funded through internal accruals.
Credit Rating & Borrowing
Long-term bank facilities (INR 871.01 Cr) are rated CARE AA+; Stable (upgraded from CARE AA; Positive in Oct 2024). Short-term facilities (INR 80.00 Cr) are rated CARE A1+. Net leverage stood at 1.43x as of March 31, 2025.
Operational Drivers
Raw Materials
Medical consumables, pharmaceutical supplies, and surgical implants represent the primary variable costs, though specific percentage breakdowns per item are not disclosed. Pharmaceutical sales alone accounted for INR 108.63 Cr of standalone revenue.
Import Sources
Not disclosed in available documents; however, procurement is managed through a centralized digital platform to ensure consistency across the 22 facilities.
Key Suppliers
Not specifically named; procurement is governed by robust internal financial control systems and standard operating procedures (SOPs).
Capacity Expansion
Current network consists of 22 facilities (hospitals and medical centers) as of March 31, 2025, up from 17 in the previous year. The company aims to double this capacity within 5 years. Max Dwarka added 303 beds and achieved EBITDA breakeven within 6 months.
Raw Material Costs
Not explicitly disclosed as a % of revenue, but the company utilizes 'Revenue Cycle Management' to minimize leakage and manage the cost of pharmaceutical supplies which are sold as part of the healthcare service.
Manufacturing Efficiency
Network occupancy levels stood at 74.5% in FY24 (compared to 76.4% in FY23). Efficiency is measured by ARPOB growth (up 12.5% YoY) and the rapid breakeven of new facilities like Dwarka.
Logistics & Distribution
Distribution of services is managed through an omnichannel digital platform, Max MyHealth, which has 9.5 Lakh registrations and 1.15 Lakh monthly active users.
Strategic Growth
Expected Growth Rate
15-20%
Growth Strategy
Growth will be achieved by doubling bed capacity over 5 years through organic expansions and M&A (e.g., Lucknow and Nagpur acquisitions). The company is also scaling asset-light models (O&M agreements like Max Dwarka) and digital platforms (Max MyHealth) to increase patient reach without heavy capital intensity.
Products & Services
Quaternary care healthcare services, inpatient procedures (2.90 Lakh in FY25), outpatient consultations (24.2 Lakh in FY25), day care procedures (0.8 Lakh in FY25), diagnostic services (Max Lab), and home healthcare (Max@Home).
Brand Portfolio
Max Healthcare, Max Lab, Max@Home, Max MyHealth, Max Healthcare Foundation.
New Products/Services
Expansion of Max Lab and Max@Home segments; Max@Home currently maintains a 20% EBITDA margin and is expected to scale rapidly.
Market Expansion
Expansion into non-metro high-growth markets including Lucknow, Nagpur, and Mohali to de-risk from Delhi-NCR concentration.
Market Share & Ranking
India's largest hospital chain by market capitalization (INR 1.1 Lakh Cr) and second largest by Revenue and EBITDA.
Strategic Alliances
O&M agreement with Muthoot Hospitals Private Limited for the 303-bed Dwarka facility; partnership with various healthcare societies (Devki Devi, Gujarmal Modi, Balaji, Lahore Hospital Society).
External Factors
Industry Trends
The industry is shifting toward digital health (omnichannel platforms) and consolidation. Max is positioned as a leader with its Max MyHealth platform and aggressive M&A strategy to capture market share in a growing but competitive sector.
Competitive Landscape
Intense competition from other established hospital brands in metro micro-markets (Noida, Lucknow, Mumbai) where capacity addition may temporarily outpace demand.
Competitive Moat
Moat is built on high brand equity ('Max Healthcare'), a dominant 75%+ position in the lucrative Delhi-NCR market, and a high-value specialty mix that drives industry-leading ARPOB. Sustainability is supported by the high switching costs of specialized quaternary care.
Macro Economic Sensitivity
Sensitive to healthcare regulatory changes and price caps on medical procedures/consumables which can constrain profitability.
Consumer Behavior
Increasing preference for digital engagement (9.5 Lakh digital registrations) and home-based healthcare services (Max@Home).
Geopolitical Risks
Minimal direct impact as operations are domestic, but global medical tourism trends affect patient volumes.
Regulatory & Governance
Industry Regulations
Subject to healthcare pricing regulations and pollution norms for biomedical waste. The company proactively engages with NATHEALTH and FICCI to influence policy discussions.
Environmental Compliance
Focus on achieving 'water neutrality' through water recharge and rejuvenation initiatives; CSR activities are managed via the Max Healthcare Foundation.
Taxation Policy Impact
The company follows Indian Accounting Standards (Ind AS). Specific effective tax rate % is not disclosed in the snippets.
Legal Contingencies
The company has a vigil mechanism and Whistle Blower Policy to report concerns. Specific pending court case values in INR are not disclosed in the provided documents.
Risk Analysis
Key Uncertainties
Regulatory intervention in healthcare pricing could impact margins; potential under-utilization of new capacity if demand growth slows in metro markets.
Geographic Concentration Risk
75% to 78% of bed capacity is concentrated in Delhi-NCR, making the company vulnerable to regional economic or regulatory shifts.
Third Party Dependencies
Dependency on Partner Healthcare Facilities (PHFs) and societies for O&M models, though rights are typically 'exclusive and irrevocable'.
Technology Obsolescence Risk
Risk of falling behind in medical technology; mitigated by continuous investment in 'state-of-the-art technology' and digital platforms.
Credit & Counterparty Risk
Complexity in billing systems for insurance/institutional payors increases the risk of revenue leakage and disputes; mitigated by robust revenue cycle management.